Publication | Open Access
CD62L is not a reliable biomarker for predicting PML risk in natalizumab-treated R-MS patients
50
Citations
10
References
2015
Year
Data from this well-controlled cohort of natalizumab-treated patients indicate that %CD62L is not a biomarker of PML risk.
| Year | Citations | |
|---|---|---|
Page 1
Page 1